pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,431 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1044Endpoints793BioPharma Dive305BioSpace226Fierce Biotech213onclive165raps82globenewswire health
therapy area
allOncology6180Rare Disease1501Cardiology1121Hematology1059Immunology1035Vaccines939Pulmonology
  • Virtual mental-health firms accelerate AI chatbot development using therapy session data
    People are turning to artificial intelligence for daily tasks, companionship and emotional support, prompting virtual mental‑health providers to explore AI solutions. Companies that were previousl…
    Endpoints · 1mo agoNeutral↗ source
  • Florida mandates EKGs for high-school athletes, but the new law may cause stress and cost
    Florida has become the first state to require electrocardiograms for high‑school athletes before they can participate in sports. The law is intended to screen for hidden heart conditions that could…
    STAT · 1mo agoRegulatoryNegative↗ source
← prev
page 61 of 98
next →
73
fda recalls51
fda medwatch45
fda press28
923
Psychiatry & CNS741
Ophthalmology437
Pain414
Endocrinology & Metabolism395
Infectious Disease373
  • FDA acting director of cell and gene therapies Vijay Kumar to depart his post
    Vijay Kumar, who has been serving as the acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products, announced he will leave his position. In an inte…
    Endpoints · 1mo agoNeutral↗ source
  • Nominations Open for 2026 Endpoints 11 Biotech Awards
    Nominations for the 2026 Endpoints 11 awards are now being accepted, with submissions due by July 15. The awards target private biotech startups that have differentiated science, strong leadership…
    Endpoints · 1mo agoNeutral↗ source
  • Student loan cap policy favors chiropractic over critical health professions, warns surgeon
    David S. Shapiro, a board-certified surgeon and physician executive, argues that the Education Department's new student-loan limits miss the realities of modern health care. The rule caps annual f…
    STAT · 1mo agoRegulatoryNegative↗ source
  • NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drug
    The New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos. The retraction was requested by two academic authors who raised concerns about…
    Endpoints · 1mo agoNegative↗ source
  • 26 states file lawsuit to halt federal Medicaid work-requirement rule
    Five New England states joined 21 others in a lawsuit filed Monday to stop a federal rule that would add work requirements to Medicaid. The states argue the new guidelines create an unfair bureaucr…
    STAT · 1mo agoRegulatoryNegative↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 1mo agoRegulatoryNeutral↗ source
  • FDA’s top gene-therapy regulator Vijay Kumar steps down amid leadership shake-up
    Vijay Kumar, the acting director of the FDA office that reviews cell and gene therapies, has announced he will leave his position. In an email to staff, Kumar said he reflected on his tenure and de…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • AstraZeneca to Pay $34 Million Settlement Over Texas Medicaid Kickback Allegations
    AstraZeneca has agreed to a $34 million settlement with the Texas attorney general over allegations that it provided improper incentives to boost prescriptions covered by Texas Medicaid. The state…
    STAT · 1mo agoRegulatoryNegative↗ source
  • J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential
    John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…
    Endpoints · 1mo agoNeutral↗ source
  • Over 200 biopharma investors urge EU governments to strengthen Europe's life-science sector
    More than 200 biopharma investors and companies have signed an open letter addressed to EU member states, calling for action to improve Europe's life‑science sector. The signatories argue that Eur…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 1mo ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 1mo ago↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 1mo ago↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal disc…
    Endpoints · 1mo ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin condit…
    Endpoints · 1mo ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisitio…
    Endpoints · 1mo ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 1mo ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 1mo ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 2mo ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 2mo ago↗ source
  • Opinion: Why the space in ‘health care’ matters
    When STAT polled our readers on ‘health care’ vs. ‘healthcare,’ about 60% of our readers voted for one word.
    STAT · 2mo ago↗ source
  • Opinion: STAT readers debate blue zones, open-access publishing fees, and more
    Keep those letters coming!
    STAT · 2mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 2mo ago↗ source